Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
- COVID-19
Aug 5, 2021
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
- COVID-19
Aug 4, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
- COVID-19
Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
- COVID-19
- Seasonal Influenza
Jun 14, 2021
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
- COVID-19
Jun 14, 2021
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- COVID-19
Jun 11, 2021
Novavax to Participate in Panel at BIO Digital 2021
- COVID-19
Jun 7, 2021
Novavax to Participate in Jefferies Virtual Healthcare Conference
- COVID-19
May 27, 2021

Show per page